questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-1 de cytochromes P450
Cytochrome P-450 CYP1B1
Cytochrome P-450 CYP1B1 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Cytochrome P-450
Analyse sanguine
Troubles métaboliques
Réactions médicamenteuses
Marqueurs biologiques
Métabolites
Évaluation clinique
Tests spécialisés
Symptômes
5
Mutations génétiques
Troubles oculaires
Variabilité génétique
Anomalies de développement
Métabolisme des médicaments
Réactions indésirables
Signes cliniques
Anomalies cutanées
Gestion des symptômes
Anomalies permanentes
Prévention
5
Dépistage génétique
Éducation à la santé
Mode de vie sain
Complications
Vaccins
Prévention des maladies
Suivi médical
Détection précoce
Conseils génétiques
Planification préventive
Traitements
5
Thérapie génique
Médicaments
Effets secondaires
Ajustement de dosage
Conseils génétiques
Suivi médical
Efficacité des traitements
Gravité de la condition
Thérapies alternatives
Efficacité non prouvée
Complications
5
Cancers
Troubles métaboliques
Intervention médicale
Complications graves
Gestion des complications
Traitements symptomatiques
Prévisibilité
Suivi approprié
Complications à long terme
Qualité de vie
Facteurs de risque
5
Antécédents familiaux
Exposition environnementale
Hérédité
Mutations génétiques
Toxines
Activité enzymatique
Sexe
Expression génétique
Habitudes alimentaires
Métabolisme
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP1B1 : Questions médicales les plus fréquentes",
"headline": "Cytochrome P-450 CYP1B1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cytochrome P-450 CYP1B1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-12",
"dateModified": "2025-03-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP1B1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Famille-1 de cytochromes P450",
"url": "https://questionsmedicales.fr/mesh/D000072461",
"about": {
"@type": "MedicalCondition",
"name": "Famille-1 de cytochromes P450",
"code": {
"@type": "MedicalCode",
"code": "D000072461",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.100"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP1B1",
"alternateName": "Cytochrome P-450 CYP1B1",
"code": {
"@type": "MedicalCode",
"code": "D065633",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Purnima Singh",
"url": "https://questionsmedicales.fr/author/Purnima%20Singh",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Shubha Ranjan Dutta",
"url": "https://questionsmedicales.fr/author/Shubha%20Ranjan%20Dutta",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Chi Young Song",
"url": "https://questionsmedicales.fr/author/Chi%20Young%20Song",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)."
}
},
{
"@type": "Person",
"name": "Frank J Gonzalez",
"url": "https://questionsmedicales.fr/author/Frank%20J%20Gonzalez",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)."
}
},
{
"@type": "Person",
"name": "Kafait U Malik",
"url": "https://questionsmedicales.fr/author/Kafait%20U%20Malik",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Caustic Ingestion: A Risk-Based Algorithm.",
"datePublished": "2022-08-18",
"url": "https://questionsmedicales.fr/article/36194047",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14309/ajg.0000000000001953"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intralesional steroids in refractory caustic esophageal stricture.",
"datePublished": "2024-07-09",
"url": "https://questionsmedicales.fr/article/39034874",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.54847/cp.2024.03.11"
}
},
{
"@type": "ScholarlyArticle",
"name": "Procedural and Surgical Interventions for Esophageal Stricture Secondary to Caustic Ingestion in Children.",
"datePublished": "2023-02-04",
"url": "https://questionsmedicales.fr/article/36878759",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jpedsurg.2023.01.048"
}
},
{
"@type": "ScholarlyArticle",
"name": "ESOPHAGOCELE DUE TO TWO TIMES CAUSTIC INGESTIONS: RESECTION THROUGH VIDEOTHORACOSCOPY.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36629686",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/0102-672020220002e1705"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Gastric pull-up in caustic stenosis: presentation of a complex clinical case].",
"datePublished": "2022-10-25",
"url": "https://questionsmedicales.fr/article/36283060",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-1 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072461"
},
{
"@type": "ListItem",
"position": 8,
"name": "Cytochrome P-450 CYP1B1",
"item": "https://questionsmedicales.fr/mesh/D065633"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cytochrome P-450 CYP1B1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cytochrome P-450 CYP1B1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cytochrome P-450 CYP1B1",
"description": "Comment diagnostiquer une anomalie de CYP1B1 ?\nQuels tests sont utilisés pour évaluer CYP1B1 ?\nQuels symptômes indiquent un problème avec CYP1B1 ?\nY a-t-il des marqueurs biologiques pour CYP1B1 ?\nLe diagnostic de CYP1B1 est-il complexe ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Caustics#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cytochrome P-450 CYP1B1",
"description": "Quels symptômes sont liés à une mutation de CYP1B1 ?\nLes symptômes de CYP1B1 varient-ils selon les individus ?\nCYP1B1 peut-il affecter le métabolisme des médicaments ?\nQuels signes cliniques sont associés à CYP1B1 ?\nLes symptômes de CYP1B1 sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Caustics#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cytochrome P-450 CYP1B1",
"description": "Comment prévenir les troubles liés à CYP1B1 ?\nLe mode de vie influence-t-il CYP1B1 ?\nDes vaccinations peuvent-elles aider avec CYP1B1 ?\nLe suivi médical régulier est-il important pour CYP1B1 ?\nLes conseils génétiques sont-ils utiles pour CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Caustics#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cytochrome P-450 CYP1B1",
"description": "Quels traitements existent pour les troubles liés à CYP1B1 ?\nPeut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?\nY a-t-il des traitements préventifs pour CYP1B1 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nDes thérapies alternatives sont-elles disponibles pour CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Caustics#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cytochrome P-450 CYP1B1",
"description": "Quelles complications peuvent survenir avec CYP1B1 ?\nLes complications de CYP1B1 sont-elles graves ?\nComment gérer les complications liées à CYP1B1 ?\nLes complications de CYP1B1 sont-elles prévisibles ?\nY a-t-il des complications à long terme avec CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Caustics#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cytochrome P-450 CYP1B1",
"description": "Quels sont les facteurs de risque pour CYP1B1 ?\nL'hérédité joue-t-elle un rôle dans CYP1B1 ?\nL'exposition à des toxines influence-t-elle CYP1B1 ?\nLe sexe influence-t-il les risques liés à CYP1B1 ?\nL'alimentation a-t-elle un impact sur CYP1B1 ?",
"url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Caustics#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de CYP1B1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses enzymatiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer CYP1B1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de métabolisme des médicaments et les analyses sanguines sont courants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec CYP1B1 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des troubles métaboliques ou des réactions médicamenteuses peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques pour CYP1B1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux de certains métabolites peuvent indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Le diagnostic de CYP1B1 est-il complexe ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être complexe, nécessitant une évaluation clinique et des tests spécialisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une mutation de CYP1B1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles oculaires, des anomalies de développement et des cancers peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes de CYP1B1 varient-ils selon les individus ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la gravité de la mutation."
}
},
{
"@type": "Question",
"name": "CYP1B1 peut-il affecter le métabolisme des médicaments ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dysfonction de CYP1B1 peut entraîner des réactions indésirables aux médicaments."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à CYP1B1 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des troubles de la vision et des anomalies cutanées peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les symptômes de CYP1B1 sont-ils réversibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à CYP1B1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut le dépistage génétique et l'éducation sur les risques."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il CYP1B1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire les risques de complications liées à CYP1B1."
}
},
{
"@type": "Question",
"name": "Des vaccinations peuvent-elles aider avec CYP1B1 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles liés à CYP1B1."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important pour CYP1B1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement les complications."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour CYP1B1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à comprendre les risques et à planifier des mesures préventives."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles liés à CYP1B1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent inclure des thérapies géniques et des médicaments spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des ajustements de dosage et des alternatives médicamenteuses peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs pour CYP1B1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques et un suivi régulier peuvent être des mesures préventives."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour tous les patients ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements peut varier selon la gravité de la condition."
}
},
{
"@type": "Question",
"name": "Des thérapies alternatives sont-elles disponibles pour CYP1B1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent être explorées, mais leur efficacité n'est pas prouvée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec CYP1B1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des cancers et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications de CYP1B1 sont-elles graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être graves et nécessiter une intervention médicale."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à CYP1B1 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut un suivi médical, des traitements symptomatiques et des interventions."
}
},
{
"@type": "Question",
"name": "Les complications de CYP1B1 sont-elles prévisibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles avec un suivi approprié."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme avec CYP1B1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour CYP1B1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et l'exposition environnementale."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans CYP1B1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations de CYP1B1 peuvent être héritées, augmentant le risque de troubles."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines influence-t-elle CYP1B1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut affecter l'activité de CYP1B1."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il les risques liés à CYP1B1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que le sexe peut influencer l'expression de CYP1B1."
}
},
{
"@type": "Question",
"name": "L'alimentation a-t-elle un impact sur CYP1B1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines habitudes alimentaires peuvent influencer l'activité de CYP1B1 et le métabolisme."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 07/03/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.).
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.).
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.).
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.).
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Federal University of Sao Joao del-Rei, Av. Sebastiao Goncalves Coelho, 400, Campus Centro-Oeste, Chanadour, Divinopolis-MG, CEP: 35501-296, Brazil.
Federal University of Minas Gerais, Av. Presidente Antonio Carlos, 667, Campus Pampulha, Belo Horizonte-MG, CEP: 31270-901, Brazil.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Federal University of Sao Joao del-Rei, Av. Sebastiao Goncalves Coelho, 400, Campus Centro-Oeste, Chanadour, Divinopolis-MG, CEP: 35501-296, Brazil.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Federal University of Sao Joao del-Rei, Av. Sebastiao Goncalves Coelho, 400, Campus Centro-Oeste, Chanadour, Divinopolis-MG, CEP: 35501-296, Brazil.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Federal University of Sao Joao del-Rei, Av. Sebastiao Goncalves Coelho, 400, Campus Centro-Oeste, Chanadour, Divinopolis-MG, CEP: 35501-296, Brazil.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmaceutical Production Center, The First Affiliated Hospital of Hunan University of Chinese Medicine, 95, Shaoshan Rd, Changsha, Hunan, 41007, China.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, E. 232, University Town, Waihuan Rd, Panyu, Guangzhou, 510006, China.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, E. 232, University Town, Waihuan Rd, Panyu, Guangzhou, 510006, China.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, E. 232, University Town, Waihuan Rd, Panyu, Guangzhou, 510006, China. Electronic address: zhouwen60@126.com.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi 835215, India.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi 835215, India.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Molecular Plant Biology, Department of Biochemistry, University of Turku, Turku FI-20014, Finland.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Institute for Chemical Research (IIQ), Scientific Research Center "Isla de la Cartuja" (cicCartuja), University of Seville - CSIC, Seville, Spain.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Institute for Chemical Research (IIQ), Scientific Research Center "Isla de la Cartuja" (cicCartuja), University of Seville - CSIC, Seville, Spain.
Publications dans "Cytochrome P-450 CYP1B1" :
2 publications dans cette catégorie
Affiliations :
Biology Department, Brookhaven National Laboratory, Upton, NY, United States.
Publications dans "Cytochrome P-450 CYP1B1" :
Caustic ingestion management could be improved with a diagnostic approach based on risk factors. This study aimed to develop an algorithm derived from predictive factors of a poor clinical course, to ...
All patients older than 15 years presenting with caustic ingestion in our tertiary care hospital between 1995 and 2021 were prospectively included. Adverse outcome was defined as intensive care unit a...
The sample included 532 cases of caustic ingestion, 13.2% (95% confidence interval [CI]: 10.3-16.0) of which had adverse outcomes. Volume and type of caustic substance; presence of symptoms and pharyn...
A risk-based algorithm could improve caustic ingestion management by maintaining high diagnostic accuracy while reducing diagnostic test requirements....
To analyze the efficacy of intralesional steroid treatment in refractory caustic esophageal stricture....
An analytical, retrospective study of patients receiving intralesional steroid treatment with triamcinolone acetonide as a result of refractory caustic esophageal stricture was carried out. Demographi...
N= 5. Median age: 5 years (17 months-7 years). Follow-up: 6.60 ± 2.70 years. Swallowed products included NaOH, KOH, and ClH. Zargar classification at follow-up initiation was IIb (n= 2), IIIa (n= 1), ...
Even though there is limited evidence available in the pediatric population, intralesional triamcinolone treatment is seemingly useful in the treatment of refractory caustic esophageal stricture, sinc...
Esophageal injury after caustic ingestion can vary in severity and may result in significant long-term morbidity due to stricture development. The optimal management remains unknown. We aim to determi...
The Pediatric Health Information System (PHIS) was utilized to identify patients 0-18 years old who experienced caustic ingestion from January 2007-September 2015 and developed subsequent esophageal s...
1,588 patients from 40 hospitals experienced caustic ingestion of which 56.6% were male, 32.5% non-Hispanic White, and the median age at time of injury was 2.2 years (IQR: 1.4,4.8). Median length of i...
Many patients with esophageal stricture after caustic ingestion will require multiple procedural interventions and potentially major surgery. These patients may benefit from early multi-disciplinary c...
III....
Caustic ingestion is still a health problem of utmost importance in the West. In developing countries, this incident remains at increase and it is associated with unfavorable factors like social, econ...
We aimed to describe a patient with multiple caustic ingestions who presented an esophagocele resected by videothoracoscopy....
A woman ingested caustic soda when she was only 17 years old in a suicidal attempt during a depressive crisis. Initially, she was submitted to a retrosternal esophagocoloplasty with the maintenance of...
The esophagocele was resected through videothoracoscopy in a prone position, employing four trocars. The postoperative was uneventful....
Esophageal exclusion must always be recorded because esophagocele presents unspecific symptoms. The videothoracoscopy in a prone position is an excellent technical option to resect esophagoceles....
Chemical substances are important causes of gastrointestinal tract injuries and usually affect two groups of patients: children under 5 years of age and adults who attempt suicide. Its effects can ran...
A clinical case of a 48-year-old male patient with no chronic degenerative history is presented, who began suffering after accidental ingestion of caustic substance 4 months ago with dysphagia to liqu...
Although associated with high rates of anastomotic stricture, transhiatal esophagectomy and gastric pull-up with cervical anastomosis are safe procedures for the treatment of caustic esophageal strict...
Ingestion of caustic agents by children is a serious health issue that can affect the patient for the rest of his life. The role of sucralfate in preventing stricture caused by caustic agents is contr...
Suicide methods chosen by victims are particularly critical in suicide risk research. To differentiate suicide deaths, it is usual to categorize them as violent and nonviolent depending on the detrime...
In this study, we retrospectively analyzed suicides that occurred between 1993 and 2021 in Milan (Italy) and that underwent autopsy. We compared a sample of 40 victims that ingested caustic substances...
Suicides by caustic ingestion showed substantial differences compared to violent suicides, with a higher severe profile. However, some differences were reported comparing caustic ingestion to other ch...
Caustic ingestion is relatively common in developing countries and can result in life-threatening sequelae. There is limited understanding of the epidemiology and incidence in Australia....
This statewide 10-year audit aims to document the rate of caustic injury in a defined Australian pouplation....
A retrospective review was conducted over 10 years (2007-2016), including all admissions to hospitals in Victoria. This includes a population of 5.9 million people and 22 hospitals....
Three hundred and eighty-four cases of caustic ingestion were admitted to hospital between January 2007 and December 2016. The overall incidence was 7 cases/million/year. This cohort included 217 (56....
Caustic ingestion remains a significant cause of morbidity and health expenditure in Victoria, particularly among vulnerable groups such as recent female migrants from areas in Africa and India. The h...
The mortality and morbidity of acute caustic gastric injuries are high. The spectrum of gastric injury due to caustic ingestion varies from hyperemia, erosion, and extensive ulcers to mucosal necrosis...
Granular myringitis (GM) is a troublesome disease with a high incidence of recurrence and relapse. CO...
Prospective and randomised study....
A total of 88 GM patients who failed therapy with boric acid, alcohol and glycerin ear drop otic solution between July 2009 and January 2018 were included. Participants were randomly assigned to recei...
Main outcomes were treatment success, complications after 4 months of treatment, and recurrence within 4-12 months after treatment....
The success rate was significantly higher in the CO...
Both TAA cauterisation and CO...